{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:52:52Z","timestamp":1781826772728,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clon.2026.104180","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:50:49Z","timestamp":1777567849000},"page":"104180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rechallenge With Immune Checkpoint Inhibitors in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0637-8773","authenticated-orcid":false,"given":"M.","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2026.104180_bib1","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clon.2026.104180_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.02.003","article-title":"Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649","author":"Janjigian","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104180_bib3","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2026.104180_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blin, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.clon.2026.104180_bib5","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104180_bib6","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blin, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104180_bib7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer","volume":"393","author":"Shitara","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2026.104180_bib8","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.2147\/DDDT.S525481","article-title":"Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study","volume":"19","author":"Chen","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clon.2026.104180_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/bjc.2014.126","article-title":"Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy","volume":"110","author":"Chiarion-Sileni","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2026.104180_bib10","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1200\/JCO.19.03315","article-title":"Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors","volume":"38","author":"Gul","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104180_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112364","article-title":"Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma","volume":"137","author":"Jin","year":"2024","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.clon.2026.104180_bib12","article-title":"Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma","volume":"5","author":"Scheiner","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.clon.2026.104180_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001945","article-title":"Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors","volume":"9","author":"Wong","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clon.2026.104180_bib14","article-title":"Efficacy and safety of immunotherapy rechallenge in second-line treatment after failure of first-line immune checkpoint inhibitors combined with chemotherapy in advanced gastric cancer: a retrospective study","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.clon.2026.104180_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2423479","article-title":"Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study","volume":"20","author":"Guo","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.clon.2026.104180_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clon.2026.104180_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clon.2026.104180_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005920","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy","volume":"11","author":"Rizvi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clon.2026.104180_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-025-02148-4","article-title":"Invasion and metastasis in cancer: molecular insights and therapeutic targets","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clon.2026.104180_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107823","article-title":"Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort","volume":"192","author":"Li","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2026.104180_bib21","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s00432-018-2702-9","article-title":"The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study","volume":"144","author":"Yang","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clon.2026.104180_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.0894-0959.2004.17603.x","article-title":"Serum albumin: relationship to inflammation and nutrition","volume":"17","author":"Don","year":"2004","journal-title":"Semin Dial"},{"key":"10.1016\/j.clon.2026.104180_bib23","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.4462","article-title":"Activation of CD4 and CD8 T cell receptors and regulatory T cells in response to human proteins","volume":"6","author":"Arneth","year":"2018","journal-title":"PeerJ"},{"key":"10.1016\/j.clon.2026.104180_bib24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/JN9.0000000000000017","article-title":"Serum albumin as a prognostic predictor reflecting host immunity in patients with non\u2013small cell lung cancer","volume":"8","author":"Li","year":"2023","journal-title":"J Nutr Oncol"},{"key":"10.1016\/j.clon.2026.104180_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/nu15194290","article-title":"The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy","volume":"15","author":"Pan","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.clon.2026.104180_bib26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ni.3754","article-title":"Nutrition, inflammation and cancer","volume":"18","author":"Zitvogel","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clon.2026.104180_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10585-013-9619-0","article-title":"Primary 4T1 tumor resection provides critical \"window of opportunity\" for immunotherapy","volume":"31","author":"Ghochikyan","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clon.2026.104180_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106705","article-title":"Complete tumor resection reverses neutrophilia-associated suppression of systemic anti-tumor immunity","volume":"150","author":"Kaskas","year":"2024","journal-title":"Oral Oncol"},{"key":"10.1016\/j.clon.2026.104180_bib29","doi-asserted-by":"crossref","first-page":"32298","DOI":"10.18632\/oncotarget.25949","article-title":"Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer","volume":"9","author":"Niki","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clon.2026.104180_bib30","doi-asserted-by":"crossref","first-page":"Of1","DOI":"10.1158\/1078-0432.CCR-22-0602","article-title":"Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)","volume":"28","author":"Akamatsu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2026.104180_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092104","article-title":"The Genetic Basis of Dormancy and Awakening in Cutaneous Metastatic Melanoma","volume":"14","author":"Janowska","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104180_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00262-020-02690-w","article-title":"Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors","volume":"70","author":"Chen","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clon.2026.104180_bib33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/jrr\/rraa077","article-title":"Radiation therapy enhanced therapeutic efficacy of anti-PD1 against gastric cancer","volume":"61","author":"Hong","year":"2020","journal-title":"J Radiat Res"},{"key":"10.1016\/j.clon.2026.104180_bib34","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clon.2026.104180_bib35","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1038\/s41467-022-34403-5","article-title":"The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction","volume":"13","author":"Tang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.clon.2026.104180_bib36","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104180_bib37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/cac2.12576","article-title":"Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors","volume":"44","author":"Wu","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.clon.2026.104180_bib38","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/j.cllc.2020.04.013","article-title":"Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients","volume":"21","author":"Gobbini","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clon.2026.104180_bib39","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/1759-7714.13483","article-title":"Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review","volume":"11","author":"Kitagawa","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.clon.2026.104180_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12943-024-02092-x","article-title":"Identification of microenvironment features associated with primary resistance to anti-PD-1\/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics","volume":"23","author":"Cousin","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clon.2026.104180_bib41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-018-0403-1","article-title":"Targeting VEGFR2 with Ramucirumab strongly impacts effector\/activated regulatory T cells and CD8(+) T cells in the tumor microenvironment","volume":"6","author":"Tada","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clon.2026.104180_bib42","article-title":"A phase 1a\/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors","volume":"4","author":"Frentzas","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.clon.2026.104180_bib43","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clon.2026.104180_bib44","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2024.42.16_suppl.4012","article-title":"Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G\/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blin, randomized trial","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104180_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.908026","article-title":"A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer","volume":"12","author":"El Helali","year":"2022","journal-title":"Front Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:24:44Z","timestamp":1781825084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526001512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"alternative-id":["S0936655526001512"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104180","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rechallenge With Immune Checkpoint Inhibitors in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"104180"}}